Skip to main content
Search
Main content
Communications medicine
Published

Predicting rates of cognitive and functional decline in Alzheimer's disease and mild cognitive impairment

Authors

Antigone Fogel, Chloe Walsh, Nan Fletcher-Lloyd, Paresh Malhotra, Mina Ryten, Ramin Nilforooshan, Payam Barnaghi

Abstract

Commun Med (Lond). 2026 Feb 26. doi: 10.1038/s43856-026-01432-w. Online ahead of print.

ABSTRACT

BACKGROUND: The global population of People Living with Dementia (PLWD) is expected to grow rapidly in the coming decades, increasing the need for personalised, generalisable, and scalable prognosis and care planning support. However, current prognostic guidance does not adequately capture the heterogeneity in dementia trajectories, and existing predictive models of dementia progression rely on costly and inaccessible data, limiting their scalability in resource-constrained settings.

METHODS: Using clinical assessments, demographic, and medical history data from 153 12-month clinical trajectories collected over three years, two machine learning algorithms were developed to predict 12-month cognitive and functional decline in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). Models were externally validated on 741 trajectories from the ADNI cohort. Cognitive and functional decline were estimated using the Mini-Mental State Exam (MMSE) and Bristol Activities of Daily Living (BADL).

RESULTS: The MMSE model achieves a mean absolute error (MAE) of 1.84 (95% CI: 1.64-2.04) internally and 2.19 in external validation. The BADL model achieves an MAE of 3.88 (95% CI: 3.46-4.30). Baseline scores on ideational praxis, orientation, and word recall are among the strongest predictors of cognitive decline, while independence in food preparation, finances, and dressing are among the top predictors of functional decline.

CONCLUSIONS: Our models use only routinely collected and easily accessible data, offering high translational potential. If implemented, our scalable, data-driven prognostic support tool could streamline clinical workflows, support personalised care planning, and provide PLWD and their families with greater clarity and reassurance.

PMID:41748878 | DOI:10.1038/s43856-026-01432-w

UK DRI Authors

Profile of Paresh Malhotra

Prof Paresh Malhotra

Group Leader

Clinically active academic neurologist specialising in cognitive disorders and dementia

Prof Paresh Malhotra
Mina Ryten

Prof Mina Ryten

Centre Director

Leveraging brain transcriptomics to understand the pathophysiology of Lewy body diseases

Prof Mina Ryten
Payam Barnaghi

Prof Payam Barnaghi

Group Leader

Combining engineering and technological innovation to produce a secure 'Healthy Home' system

Prof Payam Barnaghi